MammaPrint Genetic Test Can Reduce Use of Post-surgery Chemotherapy Among Early-stage Breast Cancer Patients
Among patients with early-stage breast cancer who were considered at high risk for disease recurrence based on clinical and biological criteria, the MammaPrint genetic test identified a large group of patients for whom five-year distant metastasis–free survival was equally good whether or not they received adjuvant chemotherapy (chemotherapy given post-surgery), according to results from the randomized, phase III microarray in node negative disease may avoid chemotherapy (MINDACT) clinical trial to be presented here at the AACR Annual Meeting 2016, April 16-20. [Weiterlesen]














Das Institut für professionelle Exzellenz hat HC Marbella mit seinem Preis „Estrella de Oro” ausgezeichnet. Hierdurch sollen die professionelle Laufbahn, das Engagement zur Exzellenz und die Vielfältigkeit der Fachbereiche anerkannt werden. Besonders hervorgehoben werden die Beiträge der 